|   News

IFM Therapeutics’ inflammation-focused subsidiary debuts with $31M


IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre. The new unit, which starts out with $31 million in series A funding, expects to bring its lead asset into phase 1 in 2019.

Read more.